Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Sep 02, 2023 11:30pm
256 Views
Post# 35617823

RE:RE:450 Day CR rate

RE:RE:450 Day CR rateThanks. Taking this into account would mean a 36% 450 day CR rate in 9 months. At that point 53 patients will have been assessed at 450 days.  The final 47 patients should do better than the first 53 because there should be no undertreated patients. So maybe a 40% 450 day CR rate at the end of the trial?

DJDawg wrote: Based on the data to date, here is the probability for the perfect streak CR patients.

Perfect CR from 90-360: 100% chance of staying CR at 450
Perfect CR from 90 to 270: 91% chance of staying CR till 450
Perfect CR from 90 to 180: 75% chance of staying CR till 450

So by my math:
- the one CR at 360 stays CR
- the 3 patients at 270 will likely convert to 3 CR's for the rest of the study. Rarely we lose one at 270.
- the 3 patients at 180: 2 of 3 will stay CR. Note that there is a CR at 180 that was a NR the CR sequence. I have little faith in those ones as there has never been a case where that scenario played out as a CR to the end.

Overall the perfect streak patients are unique as they behave differently then any of the others so far.

IMO


<< Previous
Bullboard Posts
Next >>